Qiagen invests in cancer biomarker start-up Alacris
This article was originally published in Scrip
Executive Summary
Molecular diagnostics specialist Qiagen is to acquire a minority stake in Alacris Theranostics, a German start-up developing a genome sequencing-based system to generate individually-tailored treatment strategies for cancer patients.